A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors

Status Completed

Clinical Trial Summary

Skin cancer is the most common cancer in the US, with over a million new cases diagnosed yearly. Young adults are increasingly at risk of melanoma. Contributing to the increasing skin cancer risk is the fact that US adolescents have the lowest skin protection rates of all age groups and also demonstrate increased exposure to natural and artificial UV radiation. Innovative interventions are needed to have an impact on skin cancer risk among young people. Unlike previous interventions, our skin cancer risk reduction intervention will be tailored (or personalized) to each individual participant and delivered via the Internet. The intervention will emphasize appearance concerns, which are known to be the primary motivation for UV exposure and lack of skin protection among young adults. This will be accomplished in part through the use of personalized facial images showing UV damage as well as computerized age progression demonstrations.

Primary Aim 1. To examine the efficacy of a tailored intervention delivered via the Internet designed to increase skin protection and decrease sun exposure behavior among young adults at moderate to high risk of developing skin cancer. Participants will be randomized to the tailored intervention, the Skin Cancer Foundation website, or an assessment only condition.

Aim 2. To evaluate whether sociodemographic variables (sex, race/ethnicity, skin type, family history of skin cancer), appearance consciousness, and past exposure and protective behaviors moderate intervention effects.

Aim 3. To evaluate whether Integrative Model constructs (UV-related knowledge, risk perception, beliefs, norms, self-efficacy, and intentions) mediate intervention effects.

The goals of future research would be to enhance the tailored intervention, for example, by adding additional contacts or Internet technologies or features, disseminate the intervention, assess the longevity of effects, and/or adapt the tailored intervention for use with other cancer risk behaviors or at risk groups.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Skin Neoplasms

Clinical Trial Details

NCT number	NCT02147080
Study type	Interventional
Source	Fox Chase Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	March 2011
Completion date	October 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00027586` - Imatinib Mesylate in Treating Patients With Metastatic Melanoma	Phase 2
Not yet recruiting	`NCT02230462` - Patient Satisfaction After Facial Reconstruction	N/A
Terminated	`NCT02900248` - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Completed	`NCT00224744` - Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage	Phase 3
Recruiting	`NCT06295809` - A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)	Phase 2/Phase 3
Completed	`NCT03132012` - Skin Health in Young Adults - Preventing Indoor Tanning and Promoting Sun Protection	N/A
Terminated	`NCT00865878` - ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients	Phase 2
Not yet recruiting	`NCT05359419` - Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities	Phase 4
Active, not recruiting	`NCT00001813` - Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
Completed	`NCT02046811` - Reducing Skin Cancer Risk in Childhood Cancer Survivors	N/A
Completed	`NCT00007631` - Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer	Phase 3
Completed	`NCT00847912` - CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial	Phase 4
Recruiting	`NCT02836548` - HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma	Phase 1/Phase 2
Completed	`NCT01482104` - New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)	N/A
Enrolling by invitation	`NCT04630886` - Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery	Early Phase 1
Completed	`NCT03012581` - Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types	Phase 2
Withdrawn	`NCT02813902` - A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors	Phase 1
Not yet recruiting	`NCT02408835` - Negative Pressure Wound Therapy in Groin Dissection	N/A
Completed	`NCT00204789` - Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients	Phase 2
Completed	`NCT02310503` - Spanish Registry of Mohs Surgery

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults — UV4me

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms